The use and impact of monoclonal antibody biologics during pregnancy.
作者信息
Pham-Huy Anne, Top Karina A, Constantinescu Cora, Seow Cynthia H, El-Chaâr Darine
机构信息
Division of Infectious Diseases, Immunology and Allergy (Pham-Huy), Children's Hospital of Eastern Ontario; Faculty of Medicine (Pham-Huy), University of Ottawa, Ottawa, Ont.; IWK Health Centre, Division of Infectious Diseases, Canadian Center for Vaccinology (Top), Halifax, NS; University of Calgary Faculty of Medicine, Division of Pediatric Infectious Diseases (Constantinescu); Division of Gastroenterology and Hepatology (Seow), Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alta.; OHRI OMNI Research Group (El-Chaâr), Clinical Epidemiology Program; Department of Obstetrics, Gynecology and Newborn Care (El-Chaâr), Ottawa Hospital, Ottawa, Ont.
出版信息
CMAJ. 2021 Jul 26;193(29):E1129-E1136. doi: 10.1503/cmaj.202391.
Abstract
摘要
相似文献
1
The use and impact of monoclonal antibody biologics during pregnancy.单克隆抗体生物制剂在孕期的使用及影响。
CMAJ. 2021 Jul 26;193(29):E1129-E1136. doi: 10.1503/cmaj.202391.
2
[Biologics].[生物制剂]
Z Rheumatol. 2016 Aug;75(6):604-10. doi: 10.1007/s00393-016-0122-2.
3
Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab.
Dermatology. 2008;217(4):360-1. doi: 10.1159/000156087. Epub 2008 Sep 19.
4
Safety issues of biologics in pregnant patients with rheumatic diseases.风湿病患者妊娠时使用生物制剂的安全性问题。
Ann N Y Acad Sci. 2014 May;1317:32-8. doi: 10.1111/nyas.12456. Epub 2014 May 19.
5
From mother to baby: antenatal exposure to monoclonal antibody biologics.从母亲到婴儿：产前暴露于单克隆抗体生物制剂。
Expert Rev Clin Immunol. 2019 Mar;15(3):221-229. doi: 10.1080/1744666X.2019.1561282. Epub 2019 Jan 24.
6
Treatment with biologics of pregnant patients with rheumatic diseases.风湿性疾病孕妇的生物制剂治疗。
Curr Opin Rheumatol. 2011 May;23(3):293-8. doi: 10.1097/BOR.0b013e328344a732.
7
Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.一名银屑病患者先后接受阿达木单抗、司库奇尤单抗和优特克单抗治疗后出现血小板减少症。
J Dermatol. 2019 May;46(5):e157-e158. doi: 10.1111/1346-8138.14681. Epub 2018 Oct 24.
8
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.在中重度斑块型银屑病患者中，既往生物制剂使用对布罗达umab 和乌司奴单抗疗效和安全性的影响：随机对照试验 AMAGINE-2 和 AMAGINE-3 的整合分析。
Br J Dermatol. 2018 Aug;179(2):320-328. doi: 10.1111/bjd.16464. Epub 2018 May 23.
9
[Anti-tumor necrosis factor-α medications and pregnancy].[抗肿瘤坏死因子-α药物与妊娠]
Med Clin (Barc). 2013 Sep 21;141(6):257-9. doi: 10.1016/j.medcli.2013.04.005. Epub 2013 May 20.
10
Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study.妊娠前或妊娠期间使用生物制剂的自身免疫性疾病女性发生早产和小于胎龄儿的风险：一项基于人群的队列研究。
Ann Rheum Dis. 2018 Jun;77(6):869-874. doi: 10.1136/annrheumdis-2018-213023. Epub 2018 Mar 1.
引用本文的文献
1
Efficacy and safety of casirivimab/imdevimab (REGEN-COV) in pregnant individuals with COVID-19: Literature review and insights from the COVID-19 International Drug Pregnancy Registry.卡西瑞维单抗/依米德维单抗（REGEN-COV）用于COVID-19孕妇的疗效和安全性：文献综述及COVID-19国际药物妊娠登记处的见解
Obstet Med. 2025 Jun 9:1753495X251343113. doi: 10.1177/1753495X251343113.
2
Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial.用于疟疾预防的抗子孢子单克隆抗体：一项2期随机试验的次要疗效结果
Nat Med. 2025 Jun 3. doi: 10.1038/s41591-025-03739-y.
3
Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties.尼泊卡利单抗，一种降低IgG水平且具有独特分子特性的免疫选择性FcRn阻断剂。
MAbs. 2025 Dec;17(1):2461191. doi: 10.1080/19420862.2025.2461191. Epub 2025 Feb 12.
4
Australasian hidradenitis suppurativa management guidelines.澳大利亚化脓性汗腺炎管理指南。
Australas J Dermatol. 2025 Mar;66(2):75-89. doi: 10.1111/ajd.14388. Epub 2024 Nov 22.
5
On placental and lactational transfer of IgG-based therapeutic proteins - Current understanding and knowledge gaps from a clinical pharmacology perspective.胎盘和哺乳期 IgG 类治疗性蛋白的转运：临床药理学视角下的现有认识和知识缺口。
Clin Transl Sci. 2024 Oct;17(10):e70049. doi: 10.1111/cts.70049.
6
[Drug therapy safety during pregnancy and breastfeeding].[孕期及哺乳期的药物治疗安全性]
Dermatologie (Heidelb). 2024 Nov;75(11):845-851. doi: 10.1007/s00105-024-05416-6. Epub 2024 Sep 24.
7
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases.妊娠合并慢性炎症性疾病患者培塞利珠单抗的群体药代动力学模型研究。
CPT Pharmacometrics Syst Pharmacol. 2024 Nov;13(11):1904-1914. doi: 10.1002/psp4.13220. Epub 2024 Sep 1.
8
Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.Sotrovimab 在妊娠期的应用：COVID-19 国际药物妊娠登记处的经验。
Drug Saf. 2024 Sep;47(9):843-851. doi: 10.1007/s40264-024-01439-z. Epub 2024 May 9.
9
Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity against parasites.双同型免疫球蛋白增强抗体介导的中性粒细胞对寄生虫的活性。
Front Immunol. 2024 Apr 8;15:1360220. doi: 10.3389/fimmu.2024.1360220. eCollection 2024.
10
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review.妊娠期单克隆抗体的药代动力学：系统文献复习。
Clin Pharmacokinet. 2024 May;63(5):589-622. doi: 10.1007/s40262-024-01370-7. Epub 2024 Apr 7.
本文引用的文献
1
Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants.炎症性肠病母亲及其接触生物制剂的婴儿的疫苗接种管理欠佳
Inflamm Bowel Dis. 2022 Jan 5;28(1):79-86. doi: 10.1093/ibd/izab033.
2
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.炎症性肠病女性胎儿暴露于生物制剂和硫唑嘌呤后的妊娠和新生儿结局。
Gastroenterology. 2021 Mar;160(4):1131-1139. doi: 10.1053/j.gastro.2020.11.038. Epub 2020 Nov 21.
3
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.妊娠期英夫利昔单抗、阿达木单抗和维得利珠单抗浓度以及宫内暴露后婴儿体内维得利珠单抗浓度。
Aliment Pharmacol Ther. 2020 Nov;52(10):1551-1562. doi: 10.1111/apt.16102. Epub 2020 Sep 27.
4
Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis.炎症性肠病的生物制剂及其在妊娠中的安全性：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):74-87.e3. doi: 10.1016/j.cgh.2020.09.021. Epub 2020 Sep 12.
5
Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease.母亲接受抗 TNF 治疗炎症性肠病时婴儿接种卡介苗的安全性和最佳时机。
J Crohns Colitis. 2020 Dec 2;14(12):1780-1784. doi: 10.1093/ecco-jcc/jjaa099.
6
Belimumab Concentrations in Maternal Serum and Breast Milk During Breastfeeding and the Safety Assessment of the Infant: A Case Study.哺乳期母亲血清和母乳中的贝利木单抗浓度及婴儿安全性评估：一项病例研究
Breastfeed Med. 2020 Jul;15(7):475-477. doi: 10.1089/bfm.2020.0068. Epub 2020 Apr 23.
7
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.2020 年美国风湿病学会风湿病和肌肉骨骼疾病生殖健康管理指南。
Arthritis Rheumatol. 2020 Apr;72(4):529-556. doi: 10.1002/art.41191. Epub 2020 Feb 23.
8
Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients.儿科患者单克隆抗体的药代动力学和临床药理学。
Paediatr Drugs. 2020 Apr;22(2):199-216. doi: 10.1007/s40272-020-00382-7.
9
Vaccine-derived rotavirus strains in infants in England.英格兰婴幼儿中由疫苗衍生的轮状病毒株。
Arch Dis Child. 2020 Jun;105(6):553-557. doi: 10.1136/archdischild-2019-317428. Epub 2019 Dec 23.
10
Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"?炎症性肠病的疾病监测策略：我们所说的“严格控制”是什么意思？
World J Gastroenterol. 2019 Nov 7;25(41):6172-6189. doi: 10.3748/wjg.v25.i41.6172.
Zotero 插件